SCHEMBL24868374

SCHEMBL24868374

CC(C)[C@H]1[C@H](c2ccccc2)C1(F)F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.46
HTR2A P28223 2/20 0.46
HTR2B P41595 2/20 0.46
NPSR1 Q6W5P4 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ABCB1 P08183 1/20 0.36
MAPK1 P28482 1/20 0.35
RECQL P46063 1/20 0.35
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
KCNQ4 P56696 1/20 0.33
KCNQ5 Q9NR82 1/20 0.33
MAOA P21397 11/20 0.32
MAOB P27338 11/20 0.32
KDM1A O60341 10/20 0.32
CHRNA7 P36544 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23993555 0.77 GRIA4 (0.35) HTR2CHTR2AHTR2BCHRNA7
SCHEMBL13834832 0.74 HTR2A (0.58) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL19730903 0.74 HTR2A (0.58) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL13562897 0.74 HTR2A (0.58) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL19730905 0.74 HTR2A (0.58) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL19730904 0.73 HTR2A (0.52) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL8294601 0.71 HTR2A (0.66) HTR2CHTR2AHTR2BNPSR1MEN1
SCHEMBL13893724 0.69 HTR2A (0.52) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL30312019 0.64 KDM1A (0.46) HTR2CHTR2AHTR2BMEN1KMT2A
SCHEMBL9381875 0.62 HTR2B (0.46) HTR2CHTR2AHTR2BNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-11584738-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-02-21 US disclosed
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584738-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 HTR2C 3231/4885HTR2A 1869/4885HTR2B 2680/4885
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 HTR2C 3231/4885HTR2A 1869/4885HTR2B 2680/4885
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 HTR2C 3231/4885HTR2A 1869/4885HTR2B 2680/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 HTR2C 3231/4885HTR2A 1869/4885HTR2B 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.